Injectable semaglutide shows promise for improving fertility in women with PMOS

A new proof-of-concept study demonstrates that injectable semaglutide could provide major reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS)

The treatment successfully targets infertility risks while simultaneously addressing obesity and underlying metabolic dysfunction.

Addressing a complex medical dilemma

Polyendocrine metabolic ovarian syndrome (PMOS), which was formerly known as polycystic ovary syndrome (PCOS), is a complex endocrine and metabolic disorder. Women diagnosed with PMOS frequently experience a combination of irregular menstrual cycles, elevated testosterone levels, heightened infertility risks, obesity, and cardiometabolic diseases.

Historically, patients have faced a frustrating division in their medical care, forced to choose between treatments that target reproductive symptoms and those that address metabolic health. Common existing therapies like metformin and hormonal contraceptives frequently fail to treat both reproductive and metabolic complications at the same time.

Early results from the RESTORE Trial

To find a more comprehensive approach to patient care, researchers at the University of Colorado Anschutz evaluated a subset of participants enrolled in their ongoing RESTORE clinical trial. This study is investigating how semaglutide influences ovulation and reproductive health in both adolescents and adults who have PMOS and obesity.

The initial proof-of-concept analysis focused on a group of participants between 12 and 35 years old. The research team decided to publish their preliminary findings early because positive reproductive improvements emerged much quicker than originally anticipated while the larger trial was still actively running.

Weight loss and ovulation gains

The published data indicates that the medication is highly effective when a patient responds with a body weight loss of at least 10 per cent. The results suggest that the significant weight loss and metabolic improvements brought on by the GLP-1 medication work together to help restore regular ovulation and boost overall fertility.

While GLP-1 medications have altered the landscape of modern obesity treatment, this report, published in Fertility and Sterility, stands as the first to focus specifically on how injectable semaglutide affects reproductive function and fertility within a dedicated PMOS population.

Future requirements for widespread use

The research team, which includes pediatric endocrinologists from Children’s Hospital Colorado, emphasises that these early findings are an encouraging proof of concept. Because the results are preliminary, larger and longer-term clinical studies are still required to confirm that the observed reproductive benefits are durable over time.

The RESTORE study is continuing to enrol and track participants to gather more rigorous data. However, these early indicators suggest that injectable semaglutide could eventually become a primary therapeutic option for women with PMOS who want to safely improve both their metabolic and reproductive health.